Plus Therapeutics Inc. (PSTV)
1.21
0.03 (2.54%)
At close: Jan 15, 2025, 1:51 PM
Company Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases.
Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Plus Therapeutics Inc.
| Country | United States |
| IPO Date | Jul 11, 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. Marc H. Hedrick M.B.A., M.D. |
Contact Details
Address: 4200 Marathon Boulevard Austin, Texas United States | |
| Website | https://www.plustherapeutics.com |
Stock Details
| Ticker Symbol | PSTV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001095981 |
| CUSIP Number | 72941H400 |
| ISIN Number | US72941H5090 |
| Employer ID | 33-0827593 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marc H. Hedrick M.B.A., M.D. | President, Chief Executive Officer & Director |
| Andrew J. Sims CPA | Vice President of Finance & Chief Financial Officer |
| Desiree Smith | Corporate Controller, Principal Financial & Accounting Officer |
| Dr. John K. Fraser | Chief Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 424B3 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 01, 2024 | 424B3 | Filing |
| Nov 01, 2024 | 8-K | Current Report |
| Oct 04, 2024 | S-3 | Filing |
| Sep 17, 2024 | 4 | Filing |
| Sep 16, 2024 | 4 | Filing |
| Sep 13, 2024 | 4 | Filing |
| Sep 13, 2024 | 4 | Filing |